Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
1. Ozempic
2. Rybelsus
1. Nn9535
2. Ozempic
3. Rybelsus
4. 910463-68-2
5. Nn 9535
6. Nnc 0113-0217
7. Nn-9535
8. Unii-53axn4nnhx
9. Semaglutide [usan:inn]
10. Wegovy
11. 53axn4nnhx
12. Rybelsus (oral Semaglutide)
13. Gtpl9724
14. Ozempic (injectable Semaglutide)
15. Chebi:167574
16. Ex-a2424
17. Ac-32580
18. Nnc-0113-0217
19. Rybelsus;ozempic;nn9535;og217sc;nnc 0113-0217
Molecular Weight | 4114 g/mol |
---|---|
Molecular Formula | C187H291N45O59 |
XLogP3 | -5.8 |
Hydrogen Bond Donor Count | 57 |
Hydrogen Bond Acceptor Count | 63 |
Rotatable Bond Count | 151 |
Exact Mass | 4112.1187318 g/mol |
Monoisotopic Mass | 4111.1153770 g/mol |
Topological Polar Surface Area | 1650 Ų |
Heavy Atom Count | 291 |
Formal Charge | 0 |
Complexity | 9590 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 30 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;
- in addition to other medicinal products for the treatment of diabetes.
For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4. 4, 4. 5 and 5. 1.
Treatment of obesity
Treatment of type II diabetes mellitus
Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in combination with other medicinal products for the treatment of diabetes.
For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4. 4, 4. 5 and 5. 1.
Treatment of type II diabetes mellitus
Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of
- 30 kg/m (obesity), or
- 27 kg/m to < 30 kg/m (overweight) in the presence of at least one weight-related comorbidity e. g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.
A10BJ06
A10BJ06
A10BJ06
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10B - Blood glucose lowering drugs, excl. insulins
A10BJ - Glucagon-like peptide-1 (glp-1) analogues
A10BJ06 - Semaglutide
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
GDUFA
DMF Review : Complete
Rev. Date : 2024-04-30
Pay. Date : 2023-03-02
DMF Number : 37594
Submission : 2023-03-16
Status : Active
Type : II
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40957
Submission : 2024-12-09
Status : Active
Type : II
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
GDUFA
DMF Review : Complete
Rev. Date : 2025-07-08
Pay. Date : 2025-05-15
DMF Number : 39932
Submission : 2024-05-16
Status : Active
Type : II
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39522
Submission : 2024-03-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35875
Submission : 2021-04-22
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-09-21
Pay. Date : 2021-06-10
DMF Number : 36015
Submission : 2021-08-06
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-12-20
Pay. Date : 2021-09-29
DMF Number : 36273
Submission : 2021-11-01
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-10-14
Pay. Date : 2021-07-19
DMF Number : 36101
Submission : 2021-07-12
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-10-20
Pay. Date : 2023-08-24
DMF Number : 36009
Submission : 2022-05-04
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35511
Submission : 2021-04-10
Status : Active
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Semaglutide is a GLP-1 receptor agonist, which is being investigated in Phase 3 for the treatment of weight loss type 2 diabetes and chronic kidney disease.
Lead Product(s): Semaglutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Semaglutide-Generic
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 19, 2023
Lead Product(s) : Semaglutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr Reddy’s Labs Gets Nod to Study Popular Weight Loss Medication
Details : Semaglutide is a GLP-1 receptor agonist, which is being investigated in Phase 3 for the treatment of weight loss type 2 diabetes and chronic kidney disease.
Product Name : Semaglutide-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
October 19, 2023
Details:
subcutaneous semaglutide is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults.
Lead Product(s): Semaglutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Semaglutide-Generic
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 18, 2023
Lead Product(s) : Semaglutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr Reddy's Gears up for Weight Loss Drug Study
Details : subcutaneous semaglutide is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults.
Product Name : Semaglutide-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
October 18, 2023
Details:
WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis).
Lead Product(s): Semaglutide,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Wegovy
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 16, 2025
Lead Product(s) : Semaglutide,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Wegovy For Adults With MASH And Liver Fibrosis
Details : WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis).
Product Name : Wegovy
Product Type : Peptide
Upfront Cash : Inapplicable
August 16, 2025
Details:
(S)-Pindolol Benzoate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity.
Lead Product(s): (S)-Pindolol Benzoate,Semaglutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: SCIRENT Clinical Research and Science d.o.o.
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 03, 2025
Lead Product(s) : (S)-Pindolol Benzoate,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : SCIRENT Clinical Research and Science d.o.o.
Deal Size : Inapplicable
Deal Type : Inapplicable
ACM-001.1 Effect On Lean Body Mass In Obese Patients During/Post Semaglutide Therapy
Details : (S)-Pindolol Benzoate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 03, 2025
Details:
Semaglutide is a Peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Inflammation.
Lead Product(s): Semaglutide,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 30, 2025
Lead Product(s) : Semaglutide,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effectiveness of Microdosed GLP-1 on Health, Quality of Life & Longevity
Details : Semaglutide is a Peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Inflammation.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
July 30, 2025
Details:
NNC0194-0499 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.
Lead Product(s): NNC0194-0499,Semaglutide
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 28, 2025
Lead Product(s) : NNC0194-0499,Semaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
NNC0194-0499 ± Semaglutide Safety and Efficacy In Type 1 Diabetes
Details : NNC0194-0499 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 28, 2025
Details:
Semaglutide is a Peptide drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Obesity.
Lead Product(s): Semaglutide,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Peptide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 09, 2025
Lead Product(s) : Semaglutide,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Targeting Obesity with GLP-1 Agonists to Improve Physical & Vascular Health
Details : Semaglutide is a Peptide drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
July 09, 2025
Details:
F027 (Semaglutide) is a Peptide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.
Lead Product(s): Semaglutide,Inapplicable
Therapeutic Area: Endocrinology Brand Name: F027
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 01, 2025
Lead Product(s) : Semaglutide,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase III Study of Semaglutide & Ozempic Efficacy & Safety in Type 2 Diabetes Patients
Details : F027 (Semaglutide) is a Peptide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : F027
Product Type : Peptide
Upfront Cash : Inapplicable
July 01, 2025
Details:
HDM1702 (Semaglutide) is a Peptide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Obesity.
Lead Product(s): Semaglutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: HDM1702
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 25, 2025
Lead Product(s) : Semaglutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients
Details : HDM1702 (Semaglutide) is a Peptide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Obesity.
Product Name : HDM1702
Product Type : Peptide
Upfront Cash : Inapplicable
June 25, 2025
Details:
Semaglutide is a Peptide drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Renal Insufficiency, Chronic.
Lead Product(s): Semaglutide,Inapplicable
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Peptide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 12, 2025
Lead Product(s) : Semaglutide,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
Details : Semaglutide is a Peptide drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Renal Insufficiency, Chronic.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
June 12, 2025
CAS Number : 2061897-68-3
End Use API : Semaglutide
About The Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediate...
CAS Number : 1143516-05-5
End Use API : Semaglutide
About The Company : CongenPharma, founded in 2013 and headquartered in Guangzhou, is a leading manufacturer of pharmaceutical peptide intermediates, cosmetic peptides, and ingredie...
Octadecanedioic acid mono-tert-butyl ester
CAS Number : 843666-40-0
End Use API : Semaglutide
About The Company : CongenPharma, founded in 2013 and headquartered in Guangzhou, is a leading manufacturer of pharmaceutical peptide intermediates, cosmetic peptides, and ingredie...
CAS Number : 2061897-68-3
End Use API : Semaglutide
About The Company : CongenPharma, founded in 2013 and headquartered in Guangzhou, is a leading manufacturer of pharmaceutical peptide intermediates, cosmetic peptides, and ingredie...
Boc-L-His(Trt)-Aib-L-Glu(OtBu)-Gly-OH
CAS Number : 1890228-73-5
End Use API : Semaglutide
About The Company : CongenPharma, founded in 2013 and headquartered in Guangzhou, is a leading manufacturer of pharmaceutical peptide intermediates, cosmetic peptides, and ingredie...
tBuO-Ste-L-Glu(AEEA-AEEA-OH)OtBu
CAS Number : 1118767-16-0
End Use API : Semaglutide
About The Company : CongenPharma, founded in 2013 and headquartered in Guangzhou, is a leading manufacturer of pharmaceutical peptide intermediates, cosmetic peptides, and ingredie...
Fmoc-L-Lys[tBuO-Ste-L-Glu(AEEA-AEEA)-OtBu]-OH
CAS Number : 1662688-20-1
End Use API : Semaglutide
About The Company : CongenPharma, founded in 2013 and headquartered in Guangzhou, is a leading manufacturer of pharmaceutical peptide intermediates, cosmetic peptides, and ingredie...
2-(2-(2-AMINOETHOXY)ETHOXY)ACETIC ACID HYDROCHLORI...
CAS Number : 134979-01-4
End Use API : Semaglutide
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...
17-amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecan...
CAS Number : 1143516-05-5
End Use API : Semaglutide
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...
2,2-Dimethyl-4,13-dioxo-3,8,11,17,20-pentaoxa-5,14...
CAS Number : 1069067-08-8
End Use API : Semaglutide
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...
RLD : Yes
TE Code :
Brand Name : RYBELSUS
Dosage Form : TABLET;ORAL
Dosage Strength : 3MG
Approval Date : 2019-09-20
Application Number : 213051
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : RYBELSUS
Dosage Form : TABLET;ORAL
Dosage Strength : 7MG
Approval Date : 2019-09-20
Application Number : 213051
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : RYBELSUS
Dosage Form : TABLET;ORAL
Dosage Strength : 14MG
Approval Date : 2019-09-20
Application Number : 213051
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : RYBELSUS
Dosage Form : TABLET;ORAL
Dosage Strength : 1.5MG
Approval Date : 2024-12-09
Application Number : 213051
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : RYBELSUS
Dosage Form : TABLET;ORAL
Dosage Strength : 4MG
Approval Date : 2024-12-09
Application Number : 213051
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : RYBELSUS
Dosage Form : TABLET;ORAL
Dosage Strength : 9MG
Approval Date : 2024-12-09
Application Number : 213051
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD :
TE Code :
Brand Name : RYBELSUS
Dosage Form : TABLET;ORAL
Dosage Strength : 3MG
Approval Date :
Application Number : 213182
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : RYBELSUS
Dosage Form : TABLET;ORAL
Dosage Strength : 7MG
Approval Date :
Application Number : 213182
RX/OTC/DISCN :
RLD :
TE Code :
RLD : Yes
TE Code :
Brand Name : WEGOVY
Dosage Form : SOLUTION;SUBCUTANEOUS
Dosage Strength : 0.25MG/0.5ML (0.25MG/0.5ML)
Approval Date : 2021-06-04
Application Number : 215256
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : WEGOVY
Dosage Form : SOLUTION;SUBCUTANEOUS
Dosage Strength : 0.5MG/0.5ML (0.5MG/0.5ML)
Approval Date : 2021-06-04
Application Number : 215256
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : USA
Registration Country : Greece
Brand Name :
Dosage Form : Tablet
Dosage Strength : 3MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : USA
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging :
Regulatory Info : USA
Dosage : Tablet
Dosage Strength : 3MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : USA
Registration Country : Greece
Brand Name :
Dosage Form : Tablet
Dosage Strength : 7MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : USA
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging :
Regulatory Info : USA
Dosage : Tablet
Dosage Strength : 7MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : USA
Registration Country : Greece
Brand Name :
Dosage Form : Tablet
Dosage Strength : 14MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : USA
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging :
Regulatory Info : USA
Dosage : Tablet
Dosage Strength : 14MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : USA
Registration Country : Greece
Brand Name :
Dosage Form : Injection For Subcutan...
Dosage Strength : 2MG/1.5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : USA
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging :
Regulatory Info : USA
Dosage : Injection For Subcutan...
Dosage Strength : 2MG/1.5ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info :
Registration Country : Greece
Brand Name :
Dosage Form : Solution For Injection
Dosage Strength : 2MG/1.5ML
Packaging : Pre-filled Pen
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging : Pre-filled Pen
Regulatory Info :
Dosage : Solution For Injection
Dosage Strength : 2MG/1.5ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info :
Registration Country : Greece
Brand Name :
Dosage Form : Solution For Injection
Dosage Strength : 4MG/3ML
Packaging : Pre-filled Pen
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging : Pre-filled Pen
Regulatory Info :
Dosage : Solution For Injection
Dosage Strength : 4MG/3ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Subcutaneous Pen
Dosage Strength : 0.5MG/0.5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Packaging :
Regulatory Info :
Dosage : Subcutaneous Pen
Dosage Strength : 0.5MG/0.5ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Subcutaneous Pen
Dosage Strength : 1MG/0.5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Packaging :
Regulatory Info :
Dosage : Subcutaneous Pen
Dosage Strength : 1MG/0.5ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Subcutaneous Pen
Dosage Strength : 1.7MG/0.75ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Packaging :
Regulatory Info :
Dosage : Subcutaneous Pen
Dosage Strength : 1.7MG/0.75ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Subcutaneous Pen
Dosage Strength : 2.4MG/0.75ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Packaging :
Regulatory Info :
Dosage : Subcutaneous Pen
Dosage Strength : 2.4MG/0.75ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 305
2019 Revenue in Millions : 8
Growth (%) : 3,646
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 3,450
2019 Revenue in Millions : 1,828
Growth (%) : 89
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 5,137
2020 Revenue in Millions : 3,394
Growth (%) : 59
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 737
2020 Revenue in Millions : 300
Growth (%) : 158
Main Therapeutic Indication : Nutritional Deficiency
Currency : USD
2022 Revenue in Millions : 902
2021 Revenue in Millions : 211
Growth (%) : 327
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 8,713
2021 Revenue in Millions : 5,137
Growth (%) : 70
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 1,648
2021 Revenue in Millions : 737
Growth (%) : 123
Main Therapeutic Indication : Nutritional Deficiency
Currency : USD
2023 Revenue in Millions : 4,556
2022 Revenue in Millions : 902
Growth (%) : 407
Main Therapeutic Indication : Diabetes
Currency : USD
2023 Revenue in Millions : 13,913
2022 Revenue in Millions : 8,713
Growth (%) : 60
Main Therapeutic Indication : Diabetes
Currency : USD
2023 Revenue in Millions : 2,725
2022 Revenue in Millions : 1,648
Growth (%) : 66
Market Place
Patents & EXCLUSIVITIES
Exclusivity Code : I-961
Exclusivity Expiration Date : 2028-01-28
Application Number : 209637
Product Number : 1
Exclusivity Details :
Exclusivity Code : I-961
Exclusivity Expiration Date : 2028-01-28
Application Number : 209637
Product Number : 2
Exclusivity Details :
Exclusivity Code : D-185
Exclusivity Expiration Date : 2025-03-28
Application Number : 209637
Product Number : 3
Exclusivity Details :
Exclusivity Code : I-961
Exclusivity Expiration Date : 2028-01-28
Application Number : 209637
Product Number : 3
Exclusivity Details :
Exclusivity Code : I-961
Exclusivity Expiration Date : 2028-01-28
Application Number : 209637
Product Number : 4
Exclusivity Details :
Exclusivity Code : I-935
Exclusivity Expiration Date : 2027-03-08
Application Number : 215256
Product Number : 1
Exclusivity Details :
Exclusivity Code : NPP
Exclusivity Expiration Date : 2025-12-23
Application Number : 215256
Product Number : 1
Exclusivity Details :
Exclusivity Code : I-935
Exclusivity Expiration Date : 2027-03-08
Application Number : 215256
Product Number : 2
Exclusivity Details :
Exclusivity Code : NPP
Exclusivity Expiration Date : 2025-12-23
Application Number : 215256
Product Number : 2
Exclusivity Details :
Exclusivity Code : I-935
Exclusivity Expiration Date : 2027-03-08
Application Number : 215256
Product Number : 3
Exclusivity Details :
ABOUT THIS PAGE
35
PharmaCompass offers a list of Semaglutide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Semaglutide manufacturer or Semaglutide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Semaglutide manufacturer or Semaglutide supplier.
PharmaCompass also assists you with knowing the Semaglutide API Price utilized in the formulation of products. Semaglutide API Price is not always fixed or binding as the Semaglutide Price is obtained through a variety of data sources. The Semaglutide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Semaglutide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Semaglutide, including repackagers and relabelers. The FDA regulates Semaglutide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Semaglutide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Semaglutide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Semaglutide supplier is an individual or a company that provides Semaglutide active pharmaceutical ingredient (API) or Semaglutide finished formulations upon request. The Semaglutide suppliers may include Semaglutide API manufacturers, exporters, distributors and traders.
click here to find a list of Semaglutide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Semaglutide DMF (Drug Master File) is a document detailing the whole manufacturing process of Semaglutide active pharmaceutical ingredient (API) in detail. Different forms of Semaglutide DMFs exist exist since differing nations have different regulations, such as Semaglutide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Semaglutide DMF submitted to regulatory agencies in the US is known as a USDMF. Semaglutide USDMF includes data on Semaglutide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Semaglutide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Semaglutide suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Semaglutide Drug Master File in Korea (Semaglutide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Semaglutide. The MFDS reviews the Semaglutide KDMF as part of the drug registration process and uses the information provided in the Semaglutide KDMF to evaluate the safety and efficacy of the drug.
After submitting a Semaglutide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Semaglutide API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Semaglutide suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Semaglutide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Semaglutide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Semaglutide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Semaglutide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Semaglutide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Semaglutide suppliers with NDC on PharmaCompass.
Semaglutide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Semaglutide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Semaglutide GMP manufacturer or Semaglutide GMP API supplier for your needs.
A Semaglutide CoA (Certificate of Analysis) is a formal document that attests to Semaglutide's compliance with Semaglutide specifications and serves as a tool for batch-level quality control.
Semaglutide CoA mostly includes findings from lab analyses of a specific batch. For each Semaglutide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Semaglutide may be tested according to a variety of international standards, such as European Pharmacopoeia (Semaglutide EP), Semaglutide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Semaglutide USP).